MCID: HMR003
MIFTS: 60

Hemorrhagic Disease

Categories: Immune diseases, Blood diseases, Rare diseases

Aliases & Classifications for Hemorrhagic Disease

Summaries for Hemorrhagic Disease

MalaCards based summary : Hemorrhagic Disease, also known as hemorrhagic disorders, is related to von willebrand disease, type 2 and alpha-2-plasmin inhibitor deficiency, and has symptoms including abnormal bruising, angina pectoris and chest pain. An important gene associated with Hemorrhagic Disease is F11 (Coagulation Factor XI), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Collagen chain trimerization. The drugs Bortezomib and Melphalan have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and t cells, and related phenotypes are cardiovascular system and homeostasis/metabolism

Related Diseases for Hemorrhagic Disease

Diseases in the Hemorrhagic Disease family:

Hemorrhagic Disease Due to Alpha-1-Antitrypsin Pittsburgh Mutation

Diseases related to Hemorrhagic Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 200)
# Related Disease Score Top Affiliating Genes
1 von willebrand disease, type 2 32.3 F7 F8 VWF
2 alpha-2-plasmin inhibitor deficiency 32.2 F2 SERPINC1 SERPINF2
3 von willebrand disease, type 3 32.1 F8 VWF
4 scott syndrome 32.1 F10 F2 F5
5 von willebrand disease, type 1 32.0 F2 F3 F8 VWF
6 factor vii deficiency 31.4 F10 F2 F3 F7 F8 F9
7 factor xi deficiency 31.3 F11 F2 F3 F9 SERPINC1 THBD
8 factor x deficiency 30.4 F10 F11 F2 F3 F5 F7
9 hemophilia 29.8 F2 F3 F7 F8 F9 VWF
10 hemorrhagic fever 29.8 F2 F3 ITGB3 SERPINC1
11 hemarthrosis 29.8 F10 F7 F8 F9 VWF
12 thrombotic thrombocytopenic purpura 29.8 ADAMTS13 F3 THBD VWF
13 hemophilia a 28.8 F10 F11 F3 F5 F7 F8
14 disseminated intravascular coagulation 28.0 ADAMTS13 F2 F3 F5 F7 F9
15 purpura 27.2 ADAMTS13 F2 F3 ITGA2B ITGB3 MPL
16 antithrombin, familial hemorrhagic diathesis due to 12.2
17 vitamin k deficiency hemorrhagic disease 12.0
18 hemorrhagic disease due to alpha-1-antitrypsin pittsburgh mutation 11.9
19 hermansky-pudlak syndrome 11.5
20 hermansky-pudlak syndrome 1 11.3
21 hermansky-pudlak syndrome 2 11.2
22 hermansky-pudlak syndrome 3 11.2
23 hermansky-pudlak syndrome 4 11.2
24 hermansky-pudlak syndrome 5 11.2
25 hermansky-pudlak syndrome 6 11.2
26 hermansky-pudlak syndrome 7 11.2
27 hermansky-pudlak syndrome 8 11.2
28 hermansky-pudlak syndrome 9 11.2
29 cerebral falx meningioma 11.0 F2 F3
30 fainting 10.9 F8 VWF
31 unilateral absence of a pulmonary artery 10.9 THBD VWF
32 mesenteric vascular occlusion 10.9 F2 F7
33 paracetamol poisoning 10.9 F2 F5
34 mild hemophilia a 10.9 F10 F8 VWF
35 anterior cranial fossa meningioma 10.9 F2 F3 F7
36 heparin-induced thrombocytopenia 10.9 F10 F3 SERPINC1
37 qualitative platelet defect 10.9 F2 F3 VWF
38 acquired thrombocytopenia 10.9 F11 THPO
39 subendocardial myocardial infarction 10.9 F2 SERPINA1 SERPINC1
40 blue toe syndrome 10.9 F2 F3 SERPINC1
41 thrombotic thrombocytopenic purpura, acquired 10.8 ADAMTS13 VWF
42 hepatic infarction 10.8 F2 F3 SERPINC1
43 cerebral sinovenous thrombosis 10.8 F2 F3 F5
44 livedoid vasculopathy 10.8 F2 F5
45 cardiac tamponade 10.8 F2 F8 F9
46 branch retinal artery occlusion 10.8 F2 F3 SERPINC1
47 spinal cord infarction 10.8 F2 F5 SERPINC1
48 cerebral arteritis 10.8 F8 VWF
49 hepatic vascular disease 10.8 F2 F3 SERPINC1
50 carotid artery thrombosis 10.8 F10 F3 ITGA2B

Comorbidity relations with Hemorrhagic Disease via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Cystitis
Deficiency Anemia Familial Atrial Fibrillation
Heart Disease

Graphical network of the top 20 diseases related to Hemorrhagic Disease:



Diseases related to Hemorrhagic Disease

Symptoms & Phenotypes for Hemorrhagic Disease

UMLS symptoms related to Hemorrhagic Disease:


abnormal bruising, angina pectoris, chest pain, edema

MGI Mouse Phenotypes related to Hemorrhagic Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.15 SERPINC1 ITGB3 F3 F5 THBD F7
2 homeostasis/metabolism MP:0005376 10.11 F3 SERPINF2 MPL F5 THBD F7
3 hematopoietic system MP:0005397 10.1 SERPINC1 ITGB3 F3 MPL THBD ADAMTS13
4 embryo MP:0005380 9.97 SERPINC1 ITGB3 F3 F5 THBD F9
5 immune system MP:0005387 9.77 SERPINC1 ITGB3 F3 MPL THBD ADAMTS13
6 mortality/aging MP:0010768 9.47 SERPINC1 ITGB3 F3 F5 MPL THBD

Drugs & Therapeutics for Hemorrhagic Disease

Drugs for Hemorrhagic Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 839)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bortezomib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 179324-69-7 387447 93860
2
Melphalan Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 148-82-3 4053 460612
3
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53-03-2 5865
4
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 50-02-2 5743
5
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
6
Epirubicin Approved Phase 4,Phase 3,Phase 2 56420-45-2 41867
7
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
8
Zoledronic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 118072-93-8 68740
9
Warfarin Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 81-81-2 6691 54678486
10
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
11
Thrombin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable
12
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
13
Azathioprine Approved Phase 4,Phase 3,Phase 2,Not Applicable 446-86-6 2265
14
Hydroxychloroquine Approved Phase 4,Phase 1,Phase 2 118-42-3 3652
15
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2068-78-2, 57-22-7 5978
16
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 104987-11-3 445643 439492
17
Tranexamic Acid Approved Phase 4,Phase 2,Phase 3,Not Applicable 1197-18-8 5526
18
Lenalidomide Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 191732-72-6 216326
19
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 135968-09-1
20
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 83-43-2 6741
21
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-24-8 5755
22
Amoxicillin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 26787-78-0 33613
23
Clarithromycin Approved Phase 4,Phase 2,Phase 3,Phase 1 81103-11-9 84029
24
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6, 103577-45-3 9578005
25
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
26
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
27
Dalteparin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9005-49-6
28
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9005-49-6 772 46507594
29
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 147-94-4 6253
30
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 33419-42-0 36462
31
Bevacizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 216974-75-3
32
Menthol Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 2216-51-5 16666
33
Apixaban Approved Phase 4,Phase 3,Phase 2,Not Applicable 503612-47-3 10182969
34
Iron Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7439-89-6 23925
35
Acenocoumarol Approved, Investigational Phase 4 152-72-7 9052 54676537
36 fluindione Approved, Investigational Phase 4 957-56-2
37
Phenindione Approved, Investigational Phase 4 83-12-5 4760
38
Anagrelide Approved Phase 4,Phase 3,Phase 2 68475-42-3 2182
39
Hydroxyurea Approved Phase 4,Phase 3,Phase 2,Not Applicable 127-07-1 3657
40
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 1,Phase 2,Not Applicable 9004-61-9 53477741
41
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
42
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Early Phase 1 124-94-7 31307
43
Mesna Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 3375-50-6 598
44
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 198153-51-4 5360545
45
Ribavirin Approved Phase 4,Phase 2,Phase 1 36791-04-5 37542
46
Celiprolol Approved, Investigational Phase 4 56980-93-9
47
Phentolamine Approved Phase 4 50-60-2 5775
48
Thiotepa Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 52-24-4 5453
49
Didanosine Approved Phase 4 69655-05-6 50599
50
Indinavir Approved Phase 4 150378-17-9 5362440

Interventional clinical trials:

(show top 50) (show all 3665)
# Name Status NCT ID Phase Drugs
1 Treatment of Coagulopathy Trauma-induced Guided by Thromboelastography in Politrauma Patients. Unknown status NCT02864875 Phase 4 Fibrinogen concentrate
2 The Effect of Human Albumin on Coagulation Competence and Hemorrhage Unknown status NCT02270723 Phase 4 5% Human Albumin " Behring";Lactated Ringer
3 Subclinical Joint Bleeding in Irish Adults With Severe Haemophilia A on Personalised Prophylaxis Regimens Unknown status NCT02314325 Phase 4 ADVATE [Antihemophilic Factor (Recombinant)];ADVATE [Antihemophilic Factor (Recombinant)]
4 Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma Unknown status NCT02773550 Phase 4 Bortezomib;Melphalan;Prednisone
5 Caffeic Acid Combining High-dose Dexamethasone in Management of ITP Unknown status NCT02556814 Phase 4 Caffeic acid tablets;Dexamethasone;placebo
6 Trial of HoLEP vs. PVP in Treating BPH in Patients With Bleeding Tendency Unknown status NCT02293759 Phase 4
7 A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma Unknown status NCT01868828 Phase 4 PAD;VCD
8 Study Using Plasma for Patients Requiring Emergency Surgery Unknown status NCT01221389 Phase 4 Human Plasma
9 Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma Unknown status NCT01249690 Phase 4 Bortezomib,Pirarubicin,Dexamethasone;Thalidomide,Pirarubicin,Dexamethasone
10 Stage I Multiple Myeloma Treatment Unknown status NCT00733538 Phase 4 zometa
11 Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF) Completed NCT01558739 Phase 4 INC424
12 Effect of Colloid Versus Crystalloid on Coagulation in Elective Urological Surgery Completed NCT02009033 Phase 4 Lactated Ringer;Hydroxyethylstarch
13 Anticoagulant Clinics and Vitamin K Antagonists Completed NCT00966290 Phase 4 Anticoagulant (warfarin, acenocoumarol, fluindione);Anticoagulant (warfarin, acenocoumarol, fluindione)
14 Comparison of Three Management Strategies for Post Cardiac Surgery Bleeding Completed NCT00188747 Phase 4
15 Octaplas Pediatric Plasma Replacement Trial Completed NCT02050841 Phase 4
16 Fibrinogen for Treatment of Pediatric Dilutional Coagulopathy. FibPaed Study. Completed NCT01487837 Phase 4 Human fibrinogen concentrate
17 BAY14-2222 Prophylaxis and Joint Function Improvement (Adults) Completed NCT00586521 Phase 4 Kogenate (BAY14-2222)
18 Comparison of Different Prophylaxis Regimens for Moderate to Severe Hemophilia A Pediatric Patients Completed NCT02727647 Phase 4 FVIII;FVIII
19 Efficacy and Cost Effectiveness of Pharmacokinetic Dosing in Haemophilia A Completed NCT02697370 Phase 4 Pharmacokinetic based dosage change
20 PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia A Completed NCT02492984 Phase 4 Intravenous infusions of Xyntha
21 China ADVATE PTP Study Completed NCT02170402 Phase 4
22 Prophylaxis Versus on Demand Treatment for Children With Hemophilia A Completed NCT01810666 Phase 4
23 Clinical Pharmacokinetics Study of ART-123 in Disseminated Intravascular Coagulation (DIC) Subjects With Renal Impairment Completed NCT01704001 Phase 4 ART-123
24 Fibrinogen as an Alternative to FFP in Aortic Surgery. Completed NCT00994045 Phase 4
25 Canadian Hemophilia Prophylaxis Study Completed NCT01085344 Phase 4
26 Survey of Inhibitors in Plasma-Product Exposed Toddlers Completed NCT01064284 Phase 4 PLASMA DERIVED Factor VIII;Recombinant FVIII
27 Study of Safety And Efficacy Of ReFacto AF In Previously Untreated Hemophilia A Patients In The Usual Care Setting Completed NCT00950170 Phase 4
28 Joint Status in Subjects With Severe Hemophilia A in Relation to Different Treatment Regimens Completed NCT00927667 Phase 4
29 Pharmacokinetic Study of ADVATE 3000 IU in Previously Treated Patients With Severe Hemophilia A Completed NCT00916032 Phase 4
30 Study Evaluating Safety And Efficacy Of Moroctocog Alfa (AF-CC) In Previously Treated Hemophilia A Patients Completed NCT00914459 Phase 4
31 Pharmacokinetic Comparison of Advate rAHF-PFM With Recombinate rAHF in Patients With Severe Hemophilia A Completed NCT00666406 Phase 4 Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method (rAHF-PFM);Recombinant Factor VIII (rAHF)
32 Russian Kogenate Pediatric Study Completed NCT00632814 Phase 4 rFVIII-FS (Kogenate FS, BAY14-2222) 70 IU/kg, dosing once per week;rFVIII-FS (Kogenate FS, BAY14-2222), 70 IU/kg twice per week (30 IU/kg + 40 IU/kg);rFVIII-FS (Kogenate FS, BAY14-2222) 75 IU/kg, dosing three times per week (3 x 25 IU/kg)
33 Phase 3/4 Study of a Recombinant Protein-Free Factor VIII (rAHF-PFM): Comparison of Continuous Infusion Versus Intermittent Bolus Infusion in Hemophilia A Subjects Undergoing Major Orthopedic Surgery Completed NCT00357656 Phase 4 Recombinant Protein-Free Factor VIII (rAHF-PFM);Recombinant Protein-Free Factor VIII (rAHF-PFM)
34 Dose-Response Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A Completed NCT00289536 Phase 4
35 Combination Therapy of Low Doses of rFVIIa and FEIBA for Severe Hemophilia A Patients With an Inhibitor to Factor VIII Completed NCT00284193 Phase 4 rFVIIa-FEIBA therapy for hemophilia A inhibitors;FEIBA- Activated Prothrombin Complexes
36 Prophylaxis Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A Completed NCT00243386 Phase 4 Antihemophilic factor, recombinant, manufactured protein-free;Antihemophilic factor, recombinant, manufactured protein-free
37 Study Comparing Blood Levels of ReFacto and Advante in Hemophilia A Completed NCT00168051 Phase 4 ReFacto;Advante
38 Study Evaluating ReFacto® in Hemophilia A Undergoing Major Surgery Completed NCT00092976 Phase 4 ReFacto
39 A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Patients Completed NCT00202644 Phase 4 Anagrelide;Hydroxyurea
40 Safety and Efficacy of Benefix in Patients With Hemophilia B in Usual Care Settings in China Completed NCT02336178 Phase 4 Benefix
41 Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery Completed NCT01561391 Phase 4 activated recombinant human factor VII;activated recombinant human factor VII;factor VIII
42 The Study of Different Dose Rituximab in the Treatment of ITP Completed NCT03258866 Phase 4 Rituximab;Rituximab
43 Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia Completed NCT03229746 Phase 4 Hydroxychloroquine;vincristine;azathioprine
44 Tacrolimus in Children With Henoch-Schönlein Purpura Nephritis Completed NCT03222687 Phase 4 tacrolimus;prednisone
45 Study of Voncento® in Subjects With Von Willebrand Disease Completed NCT02552576 Phase 4
46 A Comparison Study of Bypassing Agent Therapy With and Without Tranexamic Acid in Haemophilia A Patients With Inhibitor Completed NCT01800435 Phase 4 aPCC, aPCC + TXA;rFVIIa, rFVIIa + TXA
47 A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma Completed NCT02268890 Phase 4 Bortezomib
48 Severe Aortic Stenosis and Acquired Von Willebrand´s Disease: The Impact of Desmopressin in Valve-Replacement Surgery Completed NCT01994330 Phase 4 desmopressin
49 High Dose of Activated Recombinant Human Factor VII for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients With Inhibitors Completed NCT00571584 Phase 4 activated recombinant human factor VII
50 IMMUNINE Pre-Treatment Study Completed NCT01128881 Phase 4

Search NIH Clinical Center for Hemorrhagic Disease

Cochrane evidence based reviews: hemorrhagic disorders

Genetic Tests for Hemorrhagic Disease

Anatomical Context for Hemorrhagic Disease

MalaCards organs/tissues related to Hemorrhagic Disease:

41
Bone, Bone Marrow, T Cells, B Cells, Testes, Kidney, Myeloid

Publications for Hemorrhagic Disease

Articles related to Hemorrhagic Disease:

(show top 50) (show all 460)
# Title Authors Year
1
Complete Genome Sequence of <i>Epizootic hemorrhagic disease virus</i> Serotype 6, Isolated from Florida White-Tailed Deer (Odocoileus virginianus). ( 29622607 )
2018
2
Conventional and real time RT-PCR assays for the detection and differentiation of variant rabbit hemorrhagic disease virus (RHDVb) and its recombinants. ( 29024672 )
2018
3
Epizootic Hemorrhagic Disease Virus Serotype 6 Infection in Cattle, Japan, 2015. ( 29664367 )
2018
4
Hematologic Parameters and Viral Status for Zika, Chikungunya, Bluetongue, and Epizootic Hemorrhagic Disease in White-tailed Deer ( Odocoileus virginianus) on St John, US Virgin Islands. ( 29792759 )
2018
5
Adenoviral hemorrhagic disease in California mule deer, 1990-2014. ( 29582709 )
2018
6
Detection and Circulation of a Novel Rabbit Hemorrhagic Disease Virus in Australia. ( 29260677 )
2018
7
Novel subunit vaccine based on grass carp reovirus VP35 protein provides protective immunity against grass carp hemorrhagic disease. ( 29408645 )
2018
8
Recombinant canine adenovirus type 2 expressing rabbit hemorrhagic disease virus VP60 protein provided protection against RHD in rabbits. ( 29291998 )
2018
9
An Outbreak of Rabbit Hemorrhagic Disease in Finland. ( 29889007 )
2018
10
An update on the rabbit hemorrhagic disease virus (RHDV) strains circulating in Portugal in the 1990s: earliest detection of G3-G5 and G6. ( 28299483 )
2017
11
Virus Isolation and Molecular Detection of Bluetongue and Epizootic Hemorrhagic Disease Viruses from Naturally Infected White-Tailed Deer (Odocoileus virginianus). ( 28742422 )
2017
12
Epizootic hemorrhagic disease virus serotype 6 outbreak in Israeli cattle in 2015. ( 28803510 )
2017
13
Emergence of new virulent rabbit hemorrhagic disease virus strains in Saudi Arabia. ( 27913973 )
2017
14
Genomic Sequences of Epizootic Hemorrhagic Disease Viruses Isolated from Florida White-Tailed Deer. ( 29074661 )
2017
15
The First 10 Years (2006-15) of Epizootic Hemorrhagic Disease Virus Serotype 6 in the USA. ( 28657859 )
2017
16
Characterization of genome segments 2, 3 and 6 of epizootic hemorrhagic disease virus strains isolated in Japan in 1985-2013: Identification of their serotypes and geographical genetic types. ( 28506840 )
2017
17
Inclusion of an Arg-Gly-Asp receptor-recognition motif into the capsid protein of rabbit hemorrhagic disease virus enables culture of the virus in vitro. ( 28381555 )
2017
18
Binding of rabbit hemorrhagic disease virus-like particles to host histo-blood group antigens is blocked by antisera from experimentally vaccinated rabbits. ( 28780630 )
2017
19
Recombination between G2 and G6 strains of rabbit hemorrhagic disease virus (RHDV) in China. ( 27664029 )
2017
20
Dynamics of epizootic hemorrhagic disease virus infection within the vector, Culicoides sonorensis (Diptera: Ceratopogonidae). ( 29176848 )
2017
21
Adaptive diversification between the classic rabbit hemorrhagic disease virus (RHDV) and the RHDVa isolates: A genome-wide perspective. ( 28743597 )
2017
22
Identification of novel rabbit hemorrhagic disease virus B-cell epitopes and their interaction with host histo-blood group antigens. ( 26612210 )
2016
23
A new variant of rabbit hemorrhagic disease virus G2-like strain isolated in China. ( 26827930 )
2016
24
Molecular evolution of epizootic hemorrhagic disease viruses in North America based on historical isolates using motif fingerprints. ( 27107856 )
2016
25
Generation of virus like particles for epizootic hemorrhagic disease virus. ( 27473984 )
2016
26
Rabbit hemorrhagic disease virus capsid, a versatile platform for foreign B-cell epitope display inducing protective humoral immune responses. ( 27549017 )
2016
27
Host and Potential Vector Susceptibility to an Emerging Orbivirus in the United States: Epizootic Hemorrhagic Disease Virus Serotype 6. ( 26459518 )
2016
28
Self-assembly of virus-like particles of rabbit hemorrhagic disease virus capsid protein expressed in Escherichia coli and their immunogenicity in rabbits. ( 27118636 )
2016
29
Innocuity of a commercial live attenuated vaccine for epizootic hemorrhagic disease virus serotype 2 in late-term pregnant cows. ( 26876438 )
2016
30
A Thought on Possible Pathogenesis of Ebola Viral Hemorrhagic Disease and Potential Treatments: Could it Be Thrombotic Thrombocytopenic Purpura-Like Syndrome? ( 26626044 )
2016
31
Comparative analysis of rabbit hemorrhagic disease virus strains originating from outbreaks in the Russian Federation. ( 27094306 )
2016
32
Extensive characterization of a lentiviral-derived stable cell line expressing rabbit hemorrhagic disease virus VPg protein. ( 27609534 )
2016
33
Effects of myxoma virus and rabbit hemorrhagic disease virus on the physiological condition of wild European rabbits: Is blood biochemistry a useful monitoring tool? ( 27892861 )
2016
34
Review of Elephant Endotheliotropic Herpesviruses and Acute Hemorrhagic Disease. ( 26912715 )
2016
35
Development of a VLP-based vaccine in silkworm pupae against rabbit hemorrhagic disease virus. ( 27598862 )
2016
36
A Vaccine Against Rabbit Hemorrhagic Disease Virus. ( 27860554 )
2016
37
Molecular cloning of the rabbit interleukin 6 promoter: Functional characterization of rabbit hemorrhagic disease virus response elements in RK-13A cells. ( 27492646 )
2016
38
Production, Characterization, and Epitope Mapping of Monoclonal Antibodies Against Different Subtypes of Rabbit Hemorrhagic Disease Virus (RHDV). ( 26878800 )
2016
39
Co-evolution in a putative bundling signal of bluetongue and epizootic hemorrhagic disease viruses. ( 27853052 )
2016
40
Assessment of a Novel Vaccine Against Rabbit Hemorrhagic Disease Virus in Young Rabbits. ( 27834618 )
2016
41
Genetic Characterization of Epizootic Hemorrhagic Disease Virus Strains isolated from Cattle in Israel. ( 25701817 )
2015
42
Partial Sequence of a Novel Virus Isolated from Pelodiscus sinensis Hemorrhagic Disease. ( 26279281 )
2015
43
Expression of interleukin-1 beta and interleukin-6 in white-tailed deer infected with Epizootic Hemorrhagic Disease virus. ( 26741245 )
2015
44
Review of the 2012 Epizootic Hemorrhagic Disease Outbreak in Domestic Ruminants in the United States. ( 26244773 )
2015
45
Yeast Surface Display of Capsid Protein VP7 of Grass Carp Reovirus: Fundamental Investigation for the Development of Vaccine Against Hemorrhagic Disease. ( 26282690 )
2015
46
Innocent blood: a history of hemorrhagic disease of the newborn. ( 25678347 )
2015
47
Rabbit Hemorrhagic Disease Virus Variant Recombinant VP60 Protein Induces Protective Immunogenicity. ( 26198122 )
2015
48
Resolving the Origin of Rabbit Hemorrhagic Disease Virus: Insights from an Investigation of the Viral Stocks Released in Australia. ( 26378178 )
2015
49
Viral Genome-Linked Protein (VPg) Is Essential for Translation Initiation of Rabbit Hemorrhagic Disease Virus (RHDV). ( 26599265 )
2015
50
A real time Taqman RT-PCR for the detection of rabbit hemorrhagic disease virus 2 (RHDV2). ( 25823548 )
2015

Variations for Hemorrhagic Disease

Expression for Hemorrhagic Disease

Search GEO for disease gene expression data for Hemorrhagic Disease.

Pathways for Hemorrhagic Disease

Pathways related to Hemorrhagic Disease according to GeneCards Suite gene sharing:

(show all 12)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.21 F10 F11 F2 F3 F5 F7
2
Show member pathways
12.68 F10 F11 F2 F3 F5 F7
3
Show member pathways
12.03 F2 ITGB3 PF4 THBD
4 11.91 F10 F11 F2 F3 F5 F7
5 11.82 ITGA2B ITGB3 MPL THPO
6
Show member pathways
11.79 F2 ITGA2B ITGB3 MPL THPO VWF
7
Show member pathways
11.77 F10 F2 F7 F9
8 11.67 ITGA2B ITGB3 THPO
9
Show member pathways
11.64 F10 F11 F2 F3 F5 F7
10 11.62 F3 ITGB3 VWF
11 11.41 F2 ITGA2B ITGB3 VWF
12 10.85 F10 F2 F7 F9

GO Terms for Hemorrhagic Disease

Cellular components related to Hemorrhagic Disease according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum lumen GO:0005788 9.91 ADAMTS13 F10 F2 F5 F7 F8
2 cell surface GO:0009986 9.87 ADAMTS13 F3 ITGA2B ITGB3 MPL SERPINF2
3 blood microparticle GO:0072562 9.8 F2 ITGA2B SERPINC1 SERPINF2
4 Golgi lumen GO:0005796 9.71 F10 F2 F7 F9
5 endoplasmic reticulum-Golgi intermediate compartment membrane GO:0033116 9.7 F5 F8 SERPINA1
6 COPII-coated ER to Golgi transport vesicle GO:0030134 9.61 F5 F8 SERPINA1
7 platelet alpha granule membrane GO:0031092 9.55 ITGA2B ITGB3
8 platelet alpha granule GO:0031091 9.54 F5 VWF
9 platelet alpha granule lumen GO:0031093 9.5 F5 F8 PF4 PPBP SERPINA1 SERPINF2
10 extracellular space GO:0005615 9.5 ADAMTS13 F11 F2 F3 F5 F7
11 intrinsic component of external side of plasma membrane GO:0031233 9.46 F10 F3
12 serine-type peptidase complex GO:1905286 9.37 F3 F7
13 plasma membrane GO:0005886 10.29 F10 F11 F2 F3 F5 F7
14 extracellular exosome GO:0070062 10.21 F11 F2 F3 F9 ITGA2B ITGB3
15 extracellular region GO:0005576 10.06 ADAMTS13 F10 F11 F2 F3 F5

Biological processes related to Hemorrhagic Disease according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 platelet activation GO:0030168 9.91 ADAMTS13 F2 F8 ITGB3 PF4 VWF
2 ER to Golgi vesicle-mediated transport GO:0006888 9.91 F10 F2 F5 F7 F8 F9
3 cellular protein metabolic process GO:0044267 9.9 F2 F5 SERPINA1 SERPINC1
4 positive regulation of protein kinase B signaling GO:0051897 9.87 F10 F3 F7 THPO
5 platelet degranulation GO:0002576 9.81 F5 F8 ITGA2B ITGB3 PF4 PPBP
6 cell-matrix adhesion GO:0007160 9.8 ADAMTS13 ITGA2B ITGB3
7 blood coagulation GO:0007596 9.8 ADAMTS13 F10 F11 F2 F3 F5
8 integrin-mediated signaling pathway GO:0007229 9.79 ADAMTS13 ITGA2B ITGB3
9 protein processing GO:0016485 9.78 ADAMTS13 F3 F7
10 acute-phase response GO:0006953 9.78 F2 F8 SERPINA1 SERPINF2
11 COPII vesicle coating GO:0048208 9.76 F5 F8 SERPINA1
12 signal peptide processing GO:0006465 9.76 F10 F2 F7 F9
13 platelet aggregation GO:0070527 9.73 ITGA2B ITGB3 MPL
14 blood coagulation, intrinsic pathway GO:0007597 9.73 F10 F11 F2 F8 F9 VWF
15 peptidyl-glutamic acid carboxylation GO:0017187 9.71 F10 F2 F7 F9
16 positive regulation of leukocyte chemotaxis GO:0002690 9.7 F7 PF4 PPBP
17 regulation of blood coagulation GO:0030193 9.69 F11 F2 SERPINC1
18 negative regulation of fibrinolysis GO:0051918 9.67 F2 SERPINF2 THBD
19 cell-substrate adhesion GO:0031589 9.63 ITGB3 VWF
20 positive regulation of blood coagulation GO:0030194 9.62 F2 F7
21 blood coagulation, extrinsic pathway GO:0007598 9.62 F10 F3 F7 F9
22 positive regulation of positive chemotaxis GO:0050927 9.61 F3 F7
23 negative regulation of platelet activation GO:0010544 9.59 F2 THBD
24 positive regulation of platelet-derived growth factor receptor signaling pathway GO:0010641 9.55 F3 F7
25 thrombopoietin-mediated signaling pathway GO:0038163 9.54 MPL THPO
26 hemostasis GO:0007599 9.44 ADAMTS13 F10 F11 F2 F3 F5
27 proteolysis GO:0006508 10.05 ADAMTS13 F10 F11 F2 F7 F9

Molecular functions related to Hemorrhagic Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 calcium ion binding GO:0005509 9.88 ADAMTS13 F10 F2 F7 F9 THBD
2 peptidase activity GO:0008233 9.73 ADAMTS13 F10 F11 F2 F7 F9
3 heparin binding GO:0008201 9.62 F11 F2 PF4 SERPINC1
4 serine-type endopeptidase inhibitor activity GO:0004867 9.61 SERPINA1 SERPINC1 SERPINF2
5 serine-type peptidase activity GO:0008236 9.55 F10 F11 F2 F7 F9
6 CXCR chemokine receptor binding GO:0045236 9.46 PF4 PPBP
7 serine-type endopeptidase activity GO:0004252 9.43 F10 F11 F2 F3 F7 F9
8 protease binding GO:0002020 9.1 F3 ITGB3 SERPINA1 SERPINC1 SERPINF2 VWF
9 protein binding GO:0005515 10.32 ADAMTS13 F10 F11 F2 F3 F5

Sources for Hemorrhagic Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....